Vaccine production Leverage Protein Sciences’ BEVS-based proprietary system and Flublok influenza vaccine heritage to position capabilities for rapid recombinant protein production and next-generation vaccine development for clients seeking faster timelines and cost efficiency.

Collaborative development Target partnerships around GeneXpress product development and manufacturing services to co-create modern vaccines, therapeutics, and gene therapies, offering end-to-end development and scalable manufacturing capabilities.

Research antigens Offer purified antigens and antibodies to academic and biotech customers to generate recurring revenue through research reagents, enabling lab collaborations and early-stage vaccine/diagnostic program support.

Geographic licensing Explore regional licensing of influenza vaccines and BEVS-produced proteins, building on past MENA licensing activity to expand market reach and create channel partnerships in underserved or strategic regions.

Sustainability & innovation Highlight the CIPPS initiative and ongoing protein development for food and medical applications to identify cross-sector opportunities with customers seeking sustainable protein production and scalable solutions for novel products.